Article
Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.
The pharmacogenomics journal - 1 Jan 2018
Kloth J S L, Verboom M C, Swen J J, van der Straaten T, Sleijfer S, Reyners A K L, Steeghs N, Gelderblom H, Guchelaar H J, Mathijssen R H J
Abstract excerpt
This study aimed to identify single-nucleotide polymorphisms (SNPs) that are associated with outcome to treatment with sunitinib in patients with advanced gastrointestinal stromal tumors (GIST). Forty-nine SNPS involved in the pharmacokinetic and pharmacodynamic pathway of sunitinib were associated with progression-free survival (PFS) and overall survival (OS) in 127 patients with advanced GIST who have been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
